Cord blood and cord tissue publications
As busy health professionals, it can be challenging to keep up with current literature about cord blood and cord tissue banking. Insception Lifebank is dedicated to helping you stay up-to-date with the latest developments so you can help your patients make informed decisions.
Cord blood transplantation
Getting more for your marrow: Boosting hematopoietic stem cell numbers with PGE2. Exp Cell Res. Aug 2014. (Hagedorn E.J., Durand E.M., Fast E.M., Zon L.I.)
This paper reviews the latest research and future avenues for therapeutic use of PGE2, a small lipid mediator, to expand the number of hematopoietic stem cells for transplantation. Originally identified as a chemical screen in zebrafish, PGE2 is in a phase II clinical trial as a therapy for patients with leukemia and lymphoma who are undergoing umbilical cord blood transplantation.
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. July 2014. (Horwitz M.E., et al.)
In a phase I trial, researchers investigated the impact on engraftment in patients who received umbilical cord blood units that were expanded in the presence of nicotinamide. Results showed an earlier median neutrophil recovery compared to historical controls, warranting further study of the potential to broaden accessibility and reduce toxicity of umbilical cord blood transplantation.
Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol.Feb 2014. (Danby R., Rocha V.)
This review summarizes the current understanding of engraftment and immune recovery following umbilical cord blood transplantation and why this differs from allogeneic transplants using other sources of hematopoieticstem cells. It also provides a comprehensive overview of promising techniques being used to improve results, including many strategies that are in current clinical trials.
Umbilical cord blood transplantation: The first 25 years and beyond. Blood.July 2013. (Ballen K.K., Gluckman E., Broxmeyer H.E.)
This study provides a 25-year review of treatment progress using umbilical cord transplantation and discusses plans for future exploration given recent advances. The authors reviewgrowth in the field from initial treatments for related and unrelated transplants in children with a variety of disorders, to improved results for adult transplantation with new approaches.
Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med.May 2013. (Shenoy S.)
This article provides a review of improvements in outcomes for patients with sickle cell disease and why umbilical cord blood transplantation merits early consideration. It also discusses how the transplant community continues to make enormous strides in the areas of immunogenetics, stem cell expansion, conditioning regimens and supportive care.
Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. Jan 2011. (Bizzetto, R., et al.)
A retrospective study showing that among patients with hereditary bone marrow failure syndromes, related umbilical cord blood transplantation is associated with excellent outcomes. The authors also discuss how increasing cell dose and better HLA matching might provide better results in unrelated umbilical cord blood transplantation.
Cord blood hematopoietic stem cell transplantation. Stembook. May 2010. (Broxmeyer, H.E.)
This comprehensive review addresses current knowledge and potential future means to enhance the quantity, quality and engrafting activity of cord blood hematopoietic stem and progenitor stem cells. The author also covers where the field stands with regards to mesenchymal stem/stromal cells, endothelial progenitor cells and induced pluripotent stem cells from cord blood.
Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with Hurler syndrome. Biol Blood Marrow Transplant. May 2009. (Boelens J.J. et al.)
The authors conclude cord blood transplantation is a beneficial option for children with Hurler syndrome and transplant should be considered expediently given improved outcomes and the immediate availability of cord blood units.
Umbilical cord blood transplantation for acute myeloid leukemia .CurrOpinHematol. Mar 2009. (Advani A.S., Laughlin M.J.)
This study discusses recent advances in the treatment of adult acute myeloid leukemia umbilical cord blood transplant.
Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. Nov 2008. (Kurtzberg, J. et al.)
This article presents the clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.
Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol. Blood Marrow Transplant. Mar 2008. (Nietfeld J.J. et al.)
This study discusses current indications andthe lifetime probability of undergoing autologous or allogeneic HSCT. Lifetime probability is much higher than previously reported by others and may rise even higher with increases in donor availability and HSCT applicability.
Cord blood and non-hematopoietic disorder
Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr. May 2014. (Cotten CM, et al.)
Researchers conclude that collection, preparation and infusion of fresh autologous umbilical cord blood cells in infants with hypoxic-ishemic encephalopathy is feasible and that further study is needed.
Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant.July 2013. (Liao Y.)
Study authors provide a review of animal studies using stem cell therapy to treat hypoxic brain injury and discuss current human pilot studies using autologous cord blood infusions in neonates with hypoxic-ischemic encephalopathy and children with cerebral palsy.
Pluripotent possibilities: Human umbilical cord blood cell treatment after neonatal brain injury. Pediatr Neurol. May 2013. (Verina T.et al.)
This paper reviews the potential for using umbilical cord blood cell treatment for neonatal brain injury. The authors discuss progress in animal studies, which have revealed insights into the mechanisms of cord blood stem cell effects and have informed current clinical trials.
Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A. double-blind, randomized, placebo-controlled trial. Stem Cells. Mar 2013. (Min K)
In this study, researchers investigated the safety and efficacy of boosting allogeneic umbilical cord blood with recombinant human erythropoietin (rhEPO) in a group of children with cerebral palsy. The researchers evaluated motor and cognitive dysfunction as well as structural and metabolic changes in the brain.
Isolation and expansion of oligodendrocyte progenitor cells from cryopreserved human umbilical cord blood. Cytotherapy. July 2011. (Tracy E.T. et al.)
Research demonstrates that oligodendrocyte progenitor cells, which hold promise as a cellular therapy for demyelinating diseases, can be derived reliably from thawed, cryopreserved umbilical cord blood, supporting the feasibility of using these cells in human clinical trials.
Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol.Feb 2010. (Prasad V.K., Kurtzberg J.)
This paper provides a review of the scientific basis, current status and future directions for the use of cord blood and bone marrow transplantation to improve outcomes for patients with inherited metabolic diseases.
Neural progenitors, neurons and oligodendrocytes from human umbilical cord blood cells in a serum-free, feeder-free cell culture. BiochemBiophys Res Commun. Feb 2009. (Chua S.J. et al.)
The objective of this study was to determine the optimal conditions required for Lin(neg) umbilical cord blood cells to differentiate into neuronal cells and oligodendrocytes.
Identification and analysis of in vitro cultured CD45-positive cells capable of multi-lineage differentiation. Exp Cell Res. May 2007. (Rogers I. et al.)
Researchers report on a subset of cells that are capable of in vitro differentiation into multi-potential cells including cells with neuroectoderm properties.
Umbilical cord tissue mesenchymal stem cells
Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells.Apr 2014. (Nagamura-Inoue T., He H.)
In this review, the authors give a brief introduction to the various components of umbilical cord tissue as a source of mesenchymal stem cells and discuss the potential clinical utility for regenerative medicine and immunotherapy.
Umbilical cord tissue mesenchymal stem cells: Characterization and clinical applications. Curr Stem Cell Res Ther.Sep 2013. (Harris D.T.)
This paper provides an overview of the clinical applications of cord tissue and discusses how cord tissue stem cells are capable of giving rise to bone, cartilage, fat and neuron cell lineages. As such, cord tissue stem cells are candidates for developing treatments for a wide variety of cardiovascular, ophthalmic, orthopedic and neurologicaldiseases and conditions.
Utility of cryopreserved umbilical cord tissue for regenerative medicine. Curr Stem Cell Res Ther.Sep 2013. (Choudhery M.S. et al.)
The goal of this study was to determine if mesenchymal stem cells isolated from cryopreserved cord tissue are functionally equivalent to those isolated from fresh cord tissue. No significant functional differences were observed between frozen mesenchymal stem cells compared to fresh tissue.